<DOC>
	<DOCNO>NCT01012544</DOCNO>
	<brief_summary>Recent study demonstrate marked interindividual variability clopidogrel 's capacity inhibit platelet aggregation substantial proportion ( 11-34 % ) patient consider non-responders clopidogrel treatment . Variable intestinal absorption suggest contribute inconsistency response clopidogrel . However , little known intestinal absorption subject suffer stent thrombosis . The MAPCAT-study design investigate whether plasma pharmacokinetics ( represent Cmax , Tmax AUC ) 600 mg load dose significantly different subject suffer stent thrombosis subject suffer stent thrombosis .</brief_summary>
	<brief_title>Platelet Reactivity Stent Thrombosis Patients</brief_title>
	<detailed_description>Objectives : The first objective MAPCAT-study investigate whether plasma pharmacokinetics ( Cmax , Tmax AUC ) additional 600 mg load dose impaired patient history stent thrombosis . The second objective MAPCAT study investigate whether genetic polymorphism receptor , enzymes ligand involved process thrombosis haemostasis well conversion-process clopidogrel metabolite influence absolute magnitude platelet inhibition Cmax , Tmax AUC .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Patients history stent thrombosis period 20042008 . Persistent acute STsegment elevation Successful revascularization qualify hospitalization , prior study entry Acute pulmonary edema , hypotension , evidence cardiogenic shock Clinically significant liver disease End stage kidney disease require dialysis Use study entry drug strong inhibitor cytochrome P450 3A4 CYP3A5 ( i.e . clarithromycin , erythromycin , itraconazole , ketoconazole ) Contraindications antithrombotic/antiplatelet therapy Failed coronary intervention previous 2 week Malignancies Increased risk bleeding ( previous stroke past month , active bleeding bleeding diathesis , recent trauma major surgery last month , suspect aortic dissection , oral anticoagulation therapy coumarin derivate within 7 day , recent use GPIIb/IIIa inhibitor within 14 day , severe uncontrolled hypertension &gt; 180 mmHg unresponsive therapy ) Relevant hematologic deviation ( haemoglobin &lt; 100g/L ( 6,2 mmol/L ) hematocrit &lt; 34 % , platelet count &lt; 100 x 109 /L platelet count &gt; 600 x 109/L ) Known allergy clopidogrel Pregnancy ( present suspect ) uncontrolled hypertension time randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>clopidogrel</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>platelet function test</keyword>
	<keyword>platelet reactivity</keyword>
</DOC>